Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43711
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrookman-May, Sabine D.-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorFreedland, Stephen J.-
dc.contributor.authorMiladinovic, Branko-
dc.contributor.authorZhang, Ke-
dc.contributor.authorFendler, Wolfgang P.-
dc.contributor.authorFeng, Felix-
dc.contributor.authorSartor, Oliver-
dc.contributor.authorSweeney, Christopher J.-
dc.date.accessioned2024-09-10T06:11:53Z-
dc.date.available2024-09-10T06:11:53Z-
dc.date.issued2024-
dc.date.submitted2024-09-09T13:45:53Z-
dc.identifier.citationEuropean Urology, 86 (2) , p. 81 -87-
dc.identifier.urihttp://hdl.handle.net/1942/43711-
dc.description.abstractDefining meaningful endpoints for research of early-stage high-risk prostate cancer is challenging, with established measures such as overall survival and metastasis-free survival facing limitations related to feasibility and adequate reflection of patient relevance. Developing endpoints must cater to diverse perspectives across scientific, clinical, regulatory, and patient viewpoints. Endpoints such as pathological complete response, no evidence of disease, and prevention of prostate-specific antigen relapse may reflect patient benefit by accounting for diagnostic and treatment burdens.-
dc.language.isoen-
dc.publisherELSEVIER-
dc.rights2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.-
dc.subject.otherHumans-
dc.subject.otherMale-
dc.subject.otherEndpoint Determination-
dc.subject.otherProstate-Specific Antigen-
dc.subject.otherProstatic Neoplasms-
dc.titleChallenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer-
dc.typeJournal Contribution-
dc.identifier.epage87-
dc.identifier.issue2-
dc.identifier.spage81-
dc.identifier.volume86-
local.format.pages7-
local.bibliographicCitation.jcatA2-
dc.description.notesBrookman-May, SD (corresponding author), 58 Village Stn Circle, Plymouth Meeting, PA 19462 USA.-
dc.description.notessabine.brookman-may@email.de-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedEditorial Material-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.doi10.1016/j.eururo.2024.04.024-
dc.identifier.pmid38762392-
dc.identifier.isi001286909200001-
dc.contributor.orcidFreedland, Stephen/0000-0002-8104-6419; Brookman-May,-
dc.contributor.orcidSabine/0000-0003-2967-4028-
local.provider.typewosris-
local.description.affiliation[Brookman-May, Sabine D.] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany.-
local.description.affiliation[Brookman-May, Sabine D.] Janssen Res & Dev, Spring House, PA USA.-
local.description.affiliation[Buyse, Marc] Univ Hasselt, Data Sci Inst, Interuniv Inst Biostat & Stat Bioinformat I Biosta, Hasselt, Belgium.-
local.description.affiliation[Buyse, Marc] Int Drug Dev Inst, Louvain La Neuve, Belgium.-
local.description.affiliation[Freedland, Stephen J.] Cedars Sinai Med Ctr, Dept Urol, Los Angeles, CA USA.-
local.description.affiliation[Freedland, Stephen J.] Durham VA Med Ctr, Sect Urol, Durham, NC USA.-
local.description.affiliation[Miladinovic, Branko; Zhang, Ke] Janssen Res & Dev, San Diego, CA USA.-
local.description.affiliation[Fendler, Wolfgang P.] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany.-
local.description.affiliation[Fendler, Wolfgang P.] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany.-
local.description.affiliation[Feng, Felix] UCSF, Dept Med, San Francisco, CA USA.-
local.description.affiliation[Feng, Felix] UCSF, Dept Urol, San Francisco, CA USA.-
local.description.affiliation[Feng, Felix] UCSF, Dept Radiat Oncol, San Francisco, CA USA.-
local.description.affiliation[Sartor, Oliver] Mayo Clin, Rochester, MN USA.-
local.description.affiliation[Sweeney, Christopher J.] Univ Adelaide, South Australian Immunogen Canc Inst, Adelaide, Australia.-
local.uhasselt.internationalyes-
item.accessRightsRestricted Access-
item.contributorBrookman-May, Sabine D.-
item.contributorBUYSE, Marc-
item.contributorFreedland, Stephen J.-
item.contributorMiladinovic, Branko-
item.contributorZhang, Ke-
item.contributorFendler, Wolfgang P.-
item.contributorFeng, Felix-
item.contributorSartor, Oliver-
item.contributorSweeney, Christopher J.-
item.fullcitationBrookman-May, Sabine D.; BUYSE, Marc; Freedland, Stephen J.; Miladinovic, Branko; Zhang, Ke; Fendler, Wolfgang P.; Feng, Felix; Sartor, Oliver & Sweeney, Christopher J. (2024) Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer. In: European Urology, 86 (2) , p. 81 -87.-
item.fulltextWith Fulltext-
crisitem.journal.issn0302-2838-
crisitem.journal.eissn1873-7560-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting .pdf
  Restricted Access		Published version336.74 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.